Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase TRIM31 (TRIM31) is an enzyme of the tripartite motif (TRIM) family, containing RING, B-box, and coiled-coil domains. It mediates ubiquitin-dependent proteasomal degradation of specific substrates and plays a crucial role in the regulation of the immune response, inflammation (notably as a negative regulator of the NLRP3 inflammasome), hematopoietic stem cell quiescence, cell cycle control, and autophagy. Abnormal TRIM31 expression or function is associated with cancer, infection, inflammatory disorders, cardiovascular and metabolic diseases. The protein’s dualistic role in cancer—as either a tumor suppressor or promoter—depends on cellular context and the specific signaling pathways involved, notably impacting p53, mTORC1, PI3K-AKT, NF-κB, and Wnt/β-catenin. Its critical regulatory functions and disease associations position TRIM31 as a potential, yet complex, therapeutic target.
Promotes ubiquitination and proteasomal degradation of target proteins (such as NLRP3, p53, CDK8). Regulates K48- and K63-linked ubiquitination pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM31 (TRIM31).